Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.68 |
| ▸ | NR4A2 | P43354 | 5/20 | 0.67 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.60 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10769843 | 0.89 | MEN1 (0.65) | MAOBNR4A2SMPD1SRD5A2PTPN1 | |
| SCHEMBL20364678 | 0.89 | MAOB (0.71) | MAOBNR4A2SMPD1SRD5A2PTPN1 | |
| SCHEMBL3362951 | 0.89 | NR4A2 (0.70) | MAOBNR4A2SMPD1SRD5A2PTPN1 | |
| SCHEMBL14490205 | 0.87 | MAOB (0.69) | MAOBNR4A2SMPD1SRD5A2PTPN1 | |
| SCHEMBL7482212 | 0.87 | MAOB (0.61) | MAOBNR4A2SMPD1SRD5A2PTPN1 | |
| SCHEMBL16217745 | 0.85 | MAOB (0.66) | MAOBNR4A2SMPD1SRD5A2PTPN1 | |
| SCHEMBL7911423 | 0.85 | NR4A2 (0.65) | MAOBNR4A2SMPD1SRD5A2PTPN1 | |
| SCHEMBL7911418 | 0.85 | NR4A2 (0.65) | MAOBNR4A2SMPD1SRD5A2PTPN1 | |
| SCHEMBL103047 | 0.84 | MAOB (0.65) | MAOBNR4A2SRD5A2SMN1; SMN2NR4A1 | |
| SCHEMBL9419082 | 0.83 | MAOB (0.67) | MAOBNR4A2SMPD1SRD5A2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815934-B2 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | WYETH LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20120252769-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | WYETH LLC (US) | 2012-10-04 | — | — | US | disclosed |
| US-20100087661-A1 | METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE | ZENTIVA K.S. (CZ) | 2010-04-08 | — | — | US | disclosed |
| US-20090176764-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLES AS ESTROGENIC AGENTS | WYETH (US) | 2009-07-09 | — | — | US | disclosed |
| US-7449455-B2 | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | WYETH (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080021017-A1 | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | WYETH (US) | 2008-01-24 | — | — | US | disclosed |
| US-7247624-B2 | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | WYETH (US) | 2007-07-24 | — | — | US | disclosed |
| US-20070142361-A1 | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations | WYETH (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070135396-A1 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | WYETH (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135397-A1 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | WYETH (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070054895-A1 | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | WYETH (US) | 2007-03-08 | — | — | US | disclosed |
| US-4446141-A | Hypotensive piperidine derivatives | KYOWA HAKKO KOGYO CO. (JP) | 1984-05-01 | — | — | US | disclosed |
| EP-0018417-B1 | NOVEL PIPERIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KYOWA HAKKO KOGYO CO., LTD (JP) | 1982-06-30 | — | — | EP | disclosed |
| EP-0018417-A1 | Novel piperidine derivatives and pharmaceutical compositions containing them | KYOWA HAKKO KOGYO CO., LTD (JP) | 1980-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252769-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | ESR2, ESR1, CYP19A1 | MAOB 166/4885NR4A2 207/4885SMPD1 3861/4885 |
| US-20070135397-A1 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | ESR2, ESR1, CYP19A1 | MAOB 166/4885NR4A2 207/4885SMPD1 3861/4885 |
| US-20100087661-A1 | METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE | CYP19A1, CYP17A1, SHBG | MAOB 85/4885NR4A2 924/4885SMPD1 4198/4885 |
| US-20070135396-A1 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | ESR2, ESR1, CYP19A1 | MAOB 166/4885NR4A2 207/4885SMPD1 3861/4885 |
| US-20070142361-A1 | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations | ESR1, ESR2, CYP19A1 | MAOB 179/4885NR4A2 181/4885SMPD1 4108/4885 |
| US-20090176764-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLES AS ESTROGENIC AGENTS | BRCA1, ESR2, PKD2 | MAOB 1015/4885NR4A2 788/4885SMPD1 4775/4885 |
| US-20080021017-A1 | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | BRCA1, PKD2, CYP19A1 | MAOB 667/4885NR4A2 598/4885SMPD1 4839/4885 |
| US-20070054895-A1 | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | ESR2, GPER1, ESR1 | MAOB 400/4885NR4A2 74/4885SMPD1 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.